PTGS2 and colorectal cancer: To focus on the effect of COX-2 knockdown on re-sensitizing DiFi5 cells to cetuximab, which is clinically approved for treating colorectal cancer, we measured the induction of apoptosis by quantifying the percentage of Annexin V-positive cells using flow cytometry analysis.